Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here are three stocks where Wall Street may be overlooking some important risks and some alternatives with better fundamentals.
Bark (BARK)
Consensus Price Target: $35 (258% implied return)
Making a name for itself with the BarkBox, Bark (NYSE: BARK) specializes in subscription-based, personalized pet products.
Why Is BARK Risky?
- 5.2% annual revenue growth over the last five years was slower than its consumer discretionary peers
- Negative free cash flow raises questions about the return timeline for its investments
- Depletion of cash reserves could lead to a fundraising event that triggers shareholder dilution
At $9.78 per share, Bark trades at 26.6x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why BARK doesn’t pass our bar.
Elanco (ELAN)
Consensus Price Target: $29.79 (24.7% implied return)
Originally established as a division of pharmaceutical giant Eli Lilly before becoming independent in 2018, Elanco Animal Health (NYSE: ELAN) develops and sells medications, vaccines, and other health products for pets and farm animals across more than 90 countries.
Why Are We Hesitant About ELAN?
- Annual revenue growth of 4.9% over the last five years was below our standards for the healthcare sector
- Expenses have increased as a percentage of revenue over the last five years as its adjusted operating margin fell by 2.9 percentage points
- Push for growth has led to negative returns on capital, signaling value destruction
Elanco’s stock price of $23.89 implies a valuation ratio of 22.4x forward P/E. If you’re considering ELAN for your portfolio, see our FREE research report to learn more.
FirstSun Capital Bancorp (FSUN)
Consensus Price Target: $43.50 (22.7% implied return)
Tracing its roots back to 1892 when it first opened its doors in Kansas, FirstSun Capital Bancorp (NASDAQ: FSUN) operates Sunflower Bank, providing commercial and consumer banking services to businesses and individuals across the Southwest region.
Why Is FSUN Not Exciting?
- Annual revenue growth of 7.4% over the last five years was below our standards for the banking sector
- Projected tangible book value per share decline of 2.8% for the next 12 months points to tough credit quality challenges ahead
- Underwhelming 9% return on equity reflects management’s difficulties in finding profitable growth opportunities
FirstSun Capital Bancorp is trading at $35.46 per share, or 0.8x forward P/B. Check out our free in-depth research report to learn more about why FSUN doesn’t pass our bar.
Stocks We Like More
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662%. AppLovin before it ran 753%. Nvidia before it ran 1,178%. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.
